Reprint

Clinical Research on Type 2 Diabetes and Its Complications

Edited by
November 2023
322 pages
  • ISBN978-3-0365-9418-7 (Hardback)
  • ISBN978-3-0365-9419-4 (PDF)

This book is a reprint of the Special Issue Clinical Research on Type 2 Diabetes and Its Complications that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

The huge prevalence of type 2 diabetes is a leading human and economic concern worldwide. The diagnosis code of type 2 diabetes includes multiple clinical phenotypes showing different degrees of obesity, fat distribution patterns, types of dyslipidemia, and characteristics of insulin resistance syndrome. In addition, subjects with type 2 diabetes could develop different clinical trajectories, with age being a critical factor in progression. The chronic complications of type 2 diabetes are a major cause of mortality and disability, and are ranked in the top places in western countries’ scores. The pathophysiological heterogeneity of type 2 diabetes is not captured by the current classifications and guidelines. The potential for diabetes progression and complications developing is different depending on the type 2 diabetes cluster, which is mostly regardless of the degree of glycemic control. However, the impact on quality and life expectancy with the current therapeutic approach is not always the same for every individual. Clinical research is the key to reducing the burden of diabetes. New basic, digital, and clinical  approaches are obtaining useful knowledge and designing more individualized interventions to prevent, track, and treat diabetic complications. This Special Issue is a clear reflection of this methodological evolution.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
dipeptidyl peptidase-4 inhibitor; diabetes mellitus; diabetic retinopathy; progression; machine learning; diabetes mellitus; diabetic sensorimotor polyneuropathy; random forest; prediction; electrophysiology; diabetes mellitus; COVID-19; hyperglycemia; glycemic control; blood glucose monitoring; telemedicine; fibrosis; NAFLD; diabetes; screening; primary care; secondary care; diabetes mellitus; glucose variability; end-stage kidney disease; Korean National Health Insurance Corporation; microvascular complications; cardiac autonomic neuropathy; diabetic peripheral neuropathy; diabetic nephropathy; diabetic retinopathy; patient profiles; machine learning; non-alcoholic fatty liver disease; NAFLD; non-alcoholic steatohepatitis; NASH; type 2 diabetes; cardiovascular disease; cardiovascular complications; CVD; type 2 diabetes; complex intervention; behaviour change intervention; co-design; continuity of care; developing country; Ethiopia; patient participation; patient transfer; stroke outcome; diabetes mellitus; hyperglycemia; skin autofluorescence; advanced glycation end products; poststroke complications; COVID-19; obesity and diabetes mellitus type 2; research; hospitalization; primary care; risk factors; cardiovascular diseases; diabetes mellitus; type 2; gender; type 2 diabetes mellitus; bone fragility; fracture risk; bone structure; bone quality; cardiac fibrosis; diabetes mellitus; pulse wave velocity; liraglutide; body weight; obesity; hypoglycemia; meta-analysis; type 2 diabetes; nephropathy; urine albumin-creatinine ratio; machine learning; diabetes mellitus; type 2; diabetes complications; coronavirus infections; hypoglycemic agents; hospitalization; ambulatory care; comorbidity; body weight; glucagon-like peptide-1 receptor agonist; HbA1c; real-world evidence; semaglutide; SURE study; type 2 diabetes; pneumatosis intestinalis; diabetes; alpha-glucosidase inhibitors; acarbose; voglibose; miglitol; comorbidities; concomitant drugs; prednisone; immunosuppressants; n/a; type 2 diabetes; depression; sex; in-hospital mortality; hospitalization; diabetes; readmission; risk factors; diabetes mellitus; empagliflozin; SGLT-2; monocytes; endothelial cells; vascular dysfunction; chemotaxis; reactive oxygen species (ROS); glucose transport; VEGFR-2; VEGFR-1